Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)

NCT01382719 is registered in ClinicalTrials.gov with Palatin Technologies, Inc as lead sponsor.

NCT NCT01382719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01382719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)
Lead sponsor
Palatin Technologies, Inc
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
September 30, 2012
Enrollment
612 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

female sexual arousal disorder, hypoactive sexual desire disorder